CLU and non-small cell lung carcinoma: Subsequently, custirsen, an ASO targeting the gene clusterin (CLU), showed promise in Stage IIIB/IV non-small cell lung cancer (NSCLC) in a Phase I clinical trial for use in combination with cisplatin and gemcitabine (Laskin et al., 2012).